

For internal distribution only

May 16, 2024

Medicare Part D Benefit Coverage Change

As a part of our due diligence to inform all concerned of Medicare Part D Formulary Changes, the following notification is requested by CMS to be sent to all Providers.

Medicare Part D Benefit Coverage – Product removal

Product(s) Removal: Rectiv Ointment 0.4 %

Effective June 1, 2024, the brand-name drug Rectiv Ointment 0.4% will be removed from our Drug List. We will add a new generic version of the brand-name drug to the Drug List (it is called nitroglycerin ointment 0.4%).

Affected members who were prescribed these drugs prior to each effective date will continue to receive the removed product under their Part D benefit until 12/31/2024, except for members who have been converted to the generic alternatives.

The following table lists all the changes for the 2024 year so far.

Reason for change	Drug Name/Description	Date and Type of Change:	Alternate Drug (Note: Over-the-counter (OTC) drugs are not covered under the Medicare Part D benefit)
Generic Available	RECTIV OINT 0.4%	June 1, 2024 Brand drug to be replaced with generic	NITROGLYCERIN OINT 0.4%
Generic Available	VASCEPA CAPS 0.5 GM, 1 GM	April 1, 2024 Brand drug to be replaced with generic	ICOSAPENT ETHYL CAPS 0.5 GM, 1 GM
Generic Available	LIALDA TBEC 1.2 GM	March 1, 2024 Brand drug to be replaced with generic	MESALAMINE TBEC 1.2 GM
Generic Available	VOTRIENT TABS 200 MG	February 1, 2024 Brand drug to be replaced with generic	PAZOPANIB HCL TABS 200 MG
Generic Available	SYMBICORT AERO 80-4.5 MCG/ACT, 160-4.5 MCG/ACT	February 1, 2024 Brand drug to be replaced with generic	BREYNA AERO 80-4.5 MCG/ACT, 160-4.5 MCG/ACT